Controversial Debate on Hepatitis B Vaccine Recommendations Sparks Heated Discussions

A committee advising on U.S. vaccine policy is debating whether to modify the hepatitis B vaccine requirements for children. Concerns on safety, led by Robert F. Kennedy Jr., are countered by arguments citing vast scientific support. The move raises fears of increasing hepatitis B infections, leading to severe health issues.

A heated debate over the hepatitis B vaccine for U.S. children unfolded as vaccine advisers considered revising a long-standing recommendation. Under the Trump administration, the proposal challenges the mandatory birth dose policy established in 1991, citing safety concerns, but experts warn of possible health repercussions.

The newly appointed committee under Robert F. Kennedy Jr. suggests a tailored vaccine policy, limiting the hepatitis B vaccine to infants born to mothers with positive hepatitis B status. Public health experts express concern over a potential rise in infections, emphasizing liver cancer and mortality risks.

Industry giants like Sanofi, Merck, and GSK defend the vaccine's safety, while some voices in government criticize the committee's credibility. The advisory committee continues its discussions by comparing U.S. immunization schedules with other developed nations, showing stark contrasts in approach.

(With inputs from agencies.)